Clinical Scorecard: Clinical Insights: Addressing Growth Hormone Deficiency in MIRAGE Syndrome and Its Treatment Response: A Broader Perspective on Endocrine Manifestations
At a Glance
Category
Detail
Condition
MIRAGE syndrome
Key Mechanisms
Heterozygous gain-of-function mutations in the SAMD9 gene leading to growth restriction and growth hormone deficiency.
Target Population
Patients with MIRAGE syndrome, particularly those exhibiting growth failure.
Care Setting
Pediatric endocrinology and hematology/oncology collaboration.
Key Highlights
MIRAGE syndrome is characterized by severe growth restriction and panhypopituitarism.
Growth hormone therapy (rhGH) may be considered in patients with proven GHD after careful risk assessment.
The syndrome has a high risk of myelodysplastic syndrome and acute myeloid leukemia.
A case study showed significant improvement in growth velocity with rhGH therapy over six years.
Endocrine manifestations of MIRAGE syndrome are expanding beyond adrenal insufficiency.
Guideline-Based Recommendations
Diagnosis
Comprehensive hormonal testing to confirm growth hormone deficiency in patients with MIRAGE syndrome.
Management
Consider rhGH therapy in carefully selected cases with proven GHD, in collaboration with hematology/oncology.
Monitoring & Follow-up
Strict hematological monitoring during rhGH therapy due to the risk of myelodysplastic syndrome.
Risks
Inherent risk of myelodysplastic syndrome and acute myeloid leukemia associated with rhGH therapy.
Patient & Prescribing Data
Children diagnosed with MIRAGE syndrome and exhibiting growth hormone deficiency.
Growth hormone therapy has shown favorable outcomes in growth velocity and height standard deviation score.
Clinical Best Practices
Conduct a risk-benefit analysis before initiating rhGH therapy.
Collaborate with hematology/oncology teams for comprehensive patient management.
Perform brain MRI to assess pituitary gland anatomy prior to growth hormone therapy.
